Drugs / REGN-EB3
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT03719586 | Nov 2018 → Sep 2019 | Ebola hemorrhagic fever | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-10-14 | Regeneron Pharmaceuticals | Regeneron's Antibody Cocktail REGN-EB3 (Inmazeb®) is First FDA-Approved Treatment for Ebola (Zaire Ebolavirus) regeneron.com ↗ |
| 2020-07-29 | Regeneron Pharmaceuticals | BARDA Procures Regeneron's REGN-EB3 Investigational Ebola Treatment for National Preparedness regeneron.com ↗ |
| 2020-04-16 | Regeneron Pharmaceuticals | FDA Accepts for Priority Review Biologics License Application for REGN-EB3 to Treat Ebola regeneron.com ↗ |
| 2019-11-27 | Regeneron Pharmaceuticals | New England Journal of Medicine Publishes Results of Ebola Clinical Trial Confirming Superiority of Regeneron's REGN-EB3 to ZMapp in Preventing Ebola Deaths regeneron.com ↗ |
| 2019-08-12 | Regeneron Pharmaceuticals | PALM Ebola Clinical Trial Stopped Early as Regeneron's REGN-EB3 Therapy Shows Superiority to ZMapp in Preventing Ebola Deaths regeneron.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REGN-EB3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03719586 ↗ |
| Modality | Monoclonal antibody | “the triple monoclonal antibody REGN-EB3” PMID 31774950 ↗ Nov 2019 |
| Route | Intravenous | “150 mg/kg of body weight administered intravenously” NCT03719586 ↗ |